| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 124 | 2018 | 15694 | 4.420 |
Why?
|
| Tumor Suppressor Protein p53 | 29 | 2014 | 3552 | 1.630 |
Why?
|
| Tamoxifen | 16 | 2013 | 876 | 1.400 |
Why?
|
| Metformin | 6 | 2014 | 378 | 1.350 |
Why?
|
| Breast | 10 | 2011 | 1344 | 1.320 |
Why?
|
| Medical Audit | 15 | 2014 | 188 | 1.290 |
Why?
|
| Receptor, ErbB-2 | 12 | 2014 | 2518 | 1.260 |
Why?
|
| Scotland | 20 | 2013 | 38 | 1.230 |
Why?
|
| Receptors, Estrogen | 13 | 2014 | 2086 | 1.220 |
Why?
|
| Carcinoma in Situ | 7 | 2018 | 487 | 1.210 |
Why?
|
| Surgical Procedures, Operative | 6 | 2011 | 383 | 1.140 |
Why?
|
| Receptors, Progesterone | 7 | 2014 | 1392 | 1.120 |
Why?
|
| Carcinoma, Ductal, Breast | 8 | 2018 | 1216 | 1.110 |
Why?
|
| Biomarkers, Tumor | 20 | 2014 | 10331 | 1.060 |
Why?
|
| Digestive System Surgical Procedures | 3 | 2013 | 275 | 1.000 |
Why?
|
| Genes, p53 | 15 | 2013 | 1090 | 0.970 |
Why?
|
| Elasticity Imaging Techniques | 5 | 2013 | 171 | 0.950 |
Why?
|
| Neoplasms, Hormone-Dependent | 5 | 2012 | 342 | 0.950 |
Why?
|
| Antineoplastic Agents, Hormonal | 11 | 2018 | 840 | 0.910 |
Why?
|
| Female | 145 | 2018 | 141928 | 0.870 |
Why?
|
| Esophageal Neoplasms | 10 | 2012 | 3168 | 0.830 |
Why?
|
| Mastectomy | 8 | 2018 | 1534 | 0.780 |
Why?
|
| Ultrasonography, Mammary | 3 | 2012 | 380 | 0.750 |
Why?
|
| Humans | 188 | 2018 | 261506 | 0.730 |
Why?
|
| Aromatase Inhibitors | 6 | 2013 | 305 | 0.690 |
Why?
|
| Hypoglycemic Agents | 4 | 2014 | 586 | 0.670 |
Why?
|
| Cholecystectomy | 2 | 2011 | 107 | 0.650 |
Why?
|
| AMP-Activated Protein Kinases | 3 | 2014 | 413 | 0.640 |
Why?
|
| Tissue Array Analysis | 4 | 2013 | 760 | 0.630 |
Why?
|
| United Kingdom | 9 | 2018 | 257 | 0.620 |
Why?
|
| Surgery Department, Hospital | 3 | 2012 | 30 | 0.610 |
Why?
|
| Medication Adherence | 6 | 2013 | 492 | 0.600 |
Why?
|
| Mastectomy, Segmental | 6 | 2018 | 1026 | 0.570 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2018 | 10035 | 0.570 |
Why?
|
| Breast Diseases | 3 | 2012 | 201 | 0.560 |
Why?
|
| Dactinomycin | 2 | 2013 | 145 | 0.560 |
Why?
|
| Hospital Mortality | 5 | 2012 | 1274 | 0.560 |
Why?
|
| Esophagectomy | 4 | 2012 | 911 | 0.540 |
Why?
|
| Aged, 80 and over | 38 | 2018 | 29902 | 0.530 |
Why?
|
| Aged | 57 | 2018 | 70117 | 0.520 |
Why?
|
| Lymph Nodes | 6 | 2013 | 2967 | 0.520 |
Why?
|
| Chromosomes, Human, Pair 17 | 9 | 2002 | 641 | 0.520 |
Why?
|
| Cytochrome P-450 CYP2D6 | 3 | 2013 | 43 | 0.510 |
Why?
|
| Sentinel Lymph Node Biopsy | 5 | 2012 | 1415 | 0.500 |
Why?
|
| Middle Aged | 63 | 2018 | 86204 | 0.490 |
Why?
|
| Research | 3 | 2013 | 415 | 0.490 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 8 | 2014 | 507 | 0.480 |
Why?
|
| Muscle Proteins | 2 | 2012 | 549 | 0.470 |
Why?
|
| Biopsy | 7 | 2013 | 3443 | 0.460 |
Why?
|
| Adult | 52 | 2014 | 77950 | 0.450 |
Why?
|
| Radiation Tolerance | 2 | 2010 | 629 | 0.450 |
Why?
|
| Estrogen Receptor Modulators | 2 | 2010 | 112 | 0.440 |
Why?
|
| Hexokinase | 1 | 2012 | 36 | 0.440 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2012 | 61 | 0.440 |
Why?
|
| Carcinoma | 8 | 2013 | 2578 | 0.440 |
Why?
|
| Pattern Recognition, Automated | 1 | 2013 | 125 | 0.430 |
Why?
|
| Temperament | 1 | 2012 | 21 | 0.430 |
Why?
|
| Postoperative Complications | 7 | 2013 | 5542 | 0.430 |
Why?
|
| DNA, Neoplasm | 7 | 2013 | 1910 | 0.430 |
Why?
|
| Cell Line, Tumor | 29 | 2014 | 14551 | 0.430 |
Why?
|
| Prospective Studies | 19 | 2018 | 12873 | 0.430 |
Why?
|
| Phenformin | 1 | 2012 | 7 | 0.430 |
Why?
|
| Antineoplastic Agents | 13 | 2014 | 14289 | 0.420 |
Why?
|
| Tissue Banks | 1 | 2012 | 55 | 0.420 |
Why?
|
| Survival Analysis | 17 | 2018 | 9180 | 0.420 |
Why?
|
| Prealbumin | 1 | 2012 | 37 | 0.420 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2014 | 336 | 0.420 |
Why?
|
| Gene Expression Regulation, Neoplastic | 21 | 2014 | 8873 | 0.420 |
Why?
|
| Serum Amyloid A Protein | 1 | 2012 | 41 | 0.420 |
Why?
|
| Monocarboxylic Acid Transporters | 1 | 2012 | 44 | 0.420 |
Why?
|
| Apolipoprotein A-I | 1 | 2012 | 84 | 0.420 |
Why?
|
| Microscopy | 1 | 2013 | 182 | 0.410 |
Why?
|
| Prognosis | 26 | 2013 | 21713 | 0.410 |
Why?
|
| Mass Screening | 2 | 2018 | 1509 | 0.400 |
Why?
|
| Axilla | 6 | 2013 | 902 | 0.400 |
Why?
|
| Stomach Neoplasms | 8 | 2007 | 2278 | 0.400 |
Why?
|
| Cancer Care Facilities | 2 | 2013 | 884 | 0.390 |
Why?
|
| Signal Transduction | 11 | 2012 | 11965 | 0.390 |
Why?
|
| Cholecystectomy, Laparoscopic | 2 | 2011 | 68 | 0.390 |
Why?
|
| Introns | 2 | 2011 | 432 | 0.390 |
Why?
|
| Gallstones | 1 | 2011 | 62 | 0.390 |
Why?
|
| Treatment Outcome | 21 | 2018 | 32848 | 0.390 |
Why?
|
| Models, Biological | 9 | 2014 | 3254 | 0.380 |
Why?
|
| Blood Proteins | 1 | 2012 | 294 | 0.380 |
Why?
|
| RNA, Messenger | 18 | 2012 | 6150 | 0.370 |
Why?
|
| Pain, Postoperative | 2 | 2013 | 610 | 0.370 |
Why?
|
| Psychosocial Deprivation | 1 | 2010 | 8 | 0.370 |
Why?
|
| Referral and Consultation | 2 | 2013 | 899 | 0.370 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2012 | 624 | 0.360 |
Why?
|
| Cooperative Behavior | 1 | 2011 | 313 | 0.350 |
Why?
|
| Emergencies | 2 | 2011 | 202 | 0.350 |
Why?
|
| Anticarcinogenic Agents | 1 | 2012 | 362 | 0.350 |
Why?
|
| Early Detection of Cancer | 3 | 2014 | 1258 | 0.350 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2012 | 494 | 0.350 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2012 | 600 | 0.340 |
Why?
|
| Doxorubicin | 2 | 2009 | 3005 | 0.340 |
Why?
|
| Mortality | 3 | 2005 | 343 | 0.340 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2012 | 1226 | 0.340 |
Why?
|
| Chronic Pain | 1 | 2012 | 238 | 0.330 |
Why?
|
| Imidazoles | 2 | 2013 | 999 | 0.330 |
Why?
|
| Gamma Rays | 1 | 2009 | 242 | 0.330 |
Why?
|
| Gene Amplification | 2 | 2010 | 731 | 0.330 |
Why?
|
| Neoplasm Invasiveness | 7 | 2012 | 3981 | 0.320 |
Why?
|
| Peer Review | 2 | 2005 | 80 | 0.320 |
Why?
|
| Epithelium | 1 | 2010 | 720 | 0.320 |
Why?
|
| Stromal Cells | 1 | 2012 | 825 | 0.320 |
Why?
|
| Cyclin D1 | 1 | 2010 | 576 | 0.310 |
Why?
|
| Models, Animal | 1 | 2010 | 664 | 0.310 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2013 | 2359 | 0.310 |
Why?
|
| Radiotherapy, Adjuvant | 6 | 2013 | 2231 | 0.310 |
Why?
|
| Chromosome Deletion | 6 | 2001 | 1005 | 0.310 |
Why?
|
| Adaptation, Psychological | 1 | 2012 | 764 | 0.310 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 6 | 2014 | 674 | 0.310 |
Why?
|
| Piperazines | 3 | 2013 | 2101 | 0.310 |
Why?
|
| Esophagogastric Junction | 3 | 2011 | 543 | 0.310 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2013 | 1303 | 0.300 |
Why?
|
| Linkage Disequilibrium | 1 | 2008 | 460 | 0.300 |
Why?
|
| Terminal Care | 1 | 2012 | 447 | 0.300 |
Why?
|
| Cholecystitis | 1 | 2007 | 52 | 0.300 |
Why?
|
| Purines | 1 | 2009 | 273 | 0.300 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2009 | 311 | 0.300 |
Why?
|
| Neoplasm, Residual | 2 | 2013 | 1656 | 0.290 |
Why?
|
| Cyclins | 2 | 2006 | 456 | 0.290 |
Why?
|
| Flow Cytometry | 2 | 2013 | 3033 | 0.290 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2009 | 221 | 0.290 |
Why?
|
| Sensitivity and Specificity | 8 | 2013 | 4971 | 0.280 |
Why?
|
| Proteomics | 2 | 2012 | 1380 | 0.280 |
Why?
|
| Immunohistochemistry | 11 | 2012 | 7548 | 0.280 |
Why?
|
| Animals | 29 | 2014 | 59536 | 0.280 |
Why?
|
| Medical Oncology | 2 | 2011 | 1423 | 0.270 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2011 | 2594 | 0.270 |
Why?
|
| Reproducibility of Results | 9 | 2013 | 6009 | 0.270 |
Why?
|
| Phantoms, Imaging | 1 | 2011 | 1271 | 0.270 |
Why?
|
| Social Responsibility | 1 | 2005 | 92 | 0.260 |
Why?
|
| Biopsy, Needle | 6 | 2012 | 1363 | 0.260 |
Why?
|
| Neoplasm Proteins | 5 | 2008 | 3230 | 0.260 |
Why?
|
| False Negative Reactions | 1 | 2005 | 275 | 0.260 |
Why?
|
| Transforming Growth Factor beta | 5 | 2010 | 1130 | 0.260 |
Why?
|
| Neoadjuvant Therapy | 4 | 2013 | 4975 | 0.260 |
Why?
|
| Anesthesia | 2 | 2005 | 296 | 0.250 |
Why?
|
| In Situ Hybridization, Fluorescence | 4 | 2010 | 2232 | 0.250 |
Why?
|
| Intraoperative Complications | 1 | 2007 | 301 | 0.250 |
Why?
|
| Family Practice | 2 | 2012 | 125 | 0.250 |
Why?
|
| Nurse's Role | 1 | 2004 | 42 | 0.250 |
Why?
|
| Biomedical Research | 2 | 2010 | 806 | 0.250 |
Why?
|
| Mammaplasty | 3 | 2009 | 780 | 0.240 |
Why?
|
| Quality Assurance, Health Care | 3 | 2005 | 585 | 0.240 |
Why?
|
| Neovascularization, Pathologic | 2 | 2008 | 1547 | 0.240 |
Why?
|
| Chemotherapy, Adjuvant | 7 | 2018 | 3890 | 0.240 |
Why?
|
| Lymph Node Excision | 2 | 2004 | 1959 | 0.240 |
Why?
|
| Retinoids | 1 | 2004 | 164 | 0.240 |
Why?
|
| Microarray Analysis | 1 | 2005 | 392 | 0.240 |
Why?
|
| Neoplasms, Experimental | 1 | 2007 | 750 | 0.240 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2013 | 15862 | 0.240 |
Why?
|
| Lymphatic Metastasis | 10 | 2013 | 4844 | 0.240 |
Why?
|
| Mutation | 13 | 2013 | 15179 | 0.230 |
Why?
|
| Palliative Care | 3 | 2013 | 2037 | 0.230 |
Why?
|
| Protein Kinases | 1 | 2008 | 874 | 0.230 |
Why?
|
| Alleles | 8 | 1998 | 2437 | 0.230 |
Why?
|
| Mice, Nude | 7 | 2012 | 4307 | 0.230 |
Why?
|
| Estrogen Receptor alpha | 1 | 2008 | 701 | 0.230 |
Why?
|
| Chromosome Aberrations | 4 | 2002 | 1960 | 0.230 |
Why?
|
| Enzyme Activation | 4 | 2012 | 1764 | 0.230 |
Why?
|
| Estrogens | 5 | 2008 | 751 | 0.220 |
Why?
|
| Surgical Flaps | 1 | 2009 | 927 | 0.220 |
Why?
|
| Mice, SCID | 3 | 2012 | 1869 | 0.220 |
Why?
|
| Esophagoscopy | 1 | 2004 | 291 | 0.220 |
Why?
|
| Neoplasms | 10 | 2013 | 15193 | 0.210 |
Why?
|
| DNA Methylation | 7 | 2013 | 2669 | 0.210 |
Why?
|
| Mice | 18 | 2012 | 34495 | 0.210 |
Why?
|
| Cohort Studies | 14 | 2014 | 9244 | 0.210 |
Why?
|
| Endoscopy, Digestive System | 1 | 2003 | 202 | 0.210 |
Why?
|
| Transplantation, Heterologous | 5 | 2012 | 1082 | 0.210 |
Why?
|
| Phosphorylation | 8 | 2013 | 4804 | 0.210 |
Why?
|
| Vinblastine | 1 | 2003 | 453 | 0.210 |
Why?
|
| 5'-Nucleotidase | 2 | 2012 | 61 | 0.210 |
Why?
|
| Neoplasm Metastasis | 8 | 2013 | 5112 | 0.210 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2014 | 5178 | 0.210 |
Why?
|
| Drug Resistance, Multiple | 1 | 2002 | 204 | 0.200 |
Why?
|
| Ki-67 Antigen | 3 | 2013 | 666 | 0.200 |
Why?
|
| Preoperative Period | 2 | 2012 | 344 | 0.200 |
Why?
|
| CpG Islands | 6 | 2013 | 633 | 0.200 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2002 | 254 | 0.200 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 3251 | 0.200 |
Why?
|
| G2 Phase | 1 | 2001 | 206 | 0.200 |
Why?
|
| Procollagen-Proline Dioxygenase | 2 | 2012 | 46 | 0.190 |
Why?
|
| Cytochrome P-450 CYP2D6 Inhibitors | 2 | 2010 | 6 | 0.190 |
Why?
|
| Cost of Illness | 1 | 2004 | 498 | 0.190 |
Why?
|
| Guideline Adherence | 3 | 2013 | 636 | 0.190 |
Why?
|
| Xenograft Model Antitumor Assays | 6 | 2014 | 3821 | 0.190 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2003 | 639 | 0.190 |
Why?
|
| Hernia | 1 | 2000 | 46 | 0.190 |
Why?
|
| Chromosomes, Human | 1 | 2001 | 295 | 0.190 |
Why?
|
| Multivariate Analysis | 4 | 2013 | 4298 | 0.180 |
Why?
|
| Combined Modality Therapy | 6 | 2018 | 8865 | 0.180 |
Why?
|
| Proto-Oncogene Proteins | 7 | 2012 | 2488 | 0.180 |
Why?
|
| Apoptosis | 7 | 2013 | 7591 | 0.180 |
Why?
|
| Laser Therapy | 1 | 2004 | 411 | 0.180 |
Why?
|
| Adenocarcinoma | 9 | 2013 | 7789 | 0.180 |
Why?
|
| Disease-Free Survival | 7 | 2013 | 10001 | 0.180 |
Why?
|
| Patient Discharge | 1 | 2004 | 661 | 0.180 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 3 | 2013 | 168 | 0.170 |
Why?
|
| Clinical Trials as Topic | 4 | 2014 | 3719 | 0.170 |
Why?
|
| Follow-Up Studies | 12 | 2013 | 14889 | 0.170 |
Why?
|
| Disease Models, Animal | 3 | 2011 | 7222 | 0.170 |
Why?
|
| Pain Measurement | 2 | 2013 | 953 | 0.170 |
Why?
|
| DEAD-box RNA Helicases | 2 | 2011 | 255 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 4 | 2010 | 528 | 0.170 |
Why?
|
| Regression Analysis | 4 | 2011 | 1546 | 0.170 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2014 | 5539 | 0.170 |
Why?
|
| Patient Satisfaction | 1 | 2004 | 915 | 0.170 |
Why?
|
| Colorectal Neoplasms | 2 | 2013 | 3578 | 0.160 |
Why?
|
| Herniorrhaphy | 1 | 2000 | 169 | 0.160 |
Why?
|
| Male | 25 | 2013 | 123000 | 0.160 |
Why?
|
| Diagnosis, Differential | 3 | 2012 | 4744 | 0.160 |
Why?
|
| Antibodies, Monoclonal | 3 | 2010 | 4367 | 0.160 |
Why?
|
| RNA, Neoplasm | 7 | 2008 | 771 | 0.160 |
Why?
|
| Benzofurans | 2 | 2010 | 38 | 0.160 |
Why?
|
| Enzyme Inhibitors | 4 | 2012 | 1879 | 0.160 |
Why?
|
| Homeodomain Proteins | 3 | 2012 | 1143 | 0.150 |
Why?
|
| Gene Expression | 6 | 2010 | 3570 | 0.150 |
Why?
|
| Stents | 1 | 2004 | 1096 | 0.150 |
Why?
|
| Minor Surgical Procedures | 1 | 1997 | 4 | 0.150 |
Why?
|
| Groin | 1 | 1997 | 74 | 0.150 |
Why?
|
| Proteins | 2 | 1998 | 1963 | 0.150 |
Why?
|
| Gene Frequency | 2 | 2010 | 1163 | 0.150 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2011 | 7702 | 0.150 |
Why?
|
| Endoscopy, Gastrointestinal | 2 | 2006 | 375 | 0.150 |
Why?
|
| Nucleic Acid Hybridization | 5 | 2004 | 542 | 0.150 |
Why?
|
| DNA-Binding Proteins | 1 | 2010 | 4821 | 0.150 |
Why?
|
| Retrospective Studies | 12 | 2013 | 37905 | 0.150 |
Why?
|
| Predictive Value of Tests | 4 | 2013 | 4892 | 0.140 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2008 | 4549 | 0.140 |
Why?
|
| Gene Silencing | 6 | 2012 | 837 | 0.140 |
Why?
|
| Lymphocytes | 1 | 2001 | 1234 | 0.140 |
Why?
|
| Athletic Injuries | 1 | 1997 | 97 | 0.140 |
Why?
|
| Databases, Factual | 3 | 2012 | 2218 | 0.140 |
Why?
|
| Cell Cycle | 4 | 2012 | 2084 | 0.140 |
Why?
|
| Risk Assessment | 6 | 2013 | 6869 | 0.130 |
Why?
|
| Drug Interactions | 2 | 2010 | 553 | 0.130 |
Why?
|
| Azacitidine | 1 | 2001 | 1149 | 0.130 |
Why?
|
| Time Factors | 7 | 2011 | 12926 | 0.130 |
Why?
|
| Menopause | 3 | 2013 | 159 | 0.130 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2007 | 221 | 0.130 |
Why?
|
| Epigenesis, Genetic | 3 | 2012 | 1399 | 0.130 |
Why?
|
| Cognition | 2 | 2012 | 968 | 0.130 |
Why?
|
| Ultraviolet Rays | 2 | 2012 | 575 | 0.130 |
Why?
|
| Bandages | 2 | 2002 | 71 | 0.130 |
Why?
|
| Neoplasm Transplantation | 4 | 2012 | 1519 | 0.130 |
Why?
|
| Serine | 2 | 2010 | 388 | 0.120 |
Why?
|
| Incidence | 4 | 2012 | 5673 | 0.120 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2014 | 1546 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 18 | 2 | 2001 | 181 | 0.120 |
Why?
|
| Gene Expression Profiling | 5 | 2011 | 5159 | 0.120 |
Why?
|
| Histones | 2 | 2012 | 1466 | 0.120 |
Why?
|
| Neoplasm Grading | 3 | 2014 | 1742 | 0.120 |
Why?
|
| Protein Isoforms | 4 | 2011 | 842 | 0.120 |
Why?
|
| Protein Biosynthesis | 3 | 2013 | 889 | 0.120 |
Why?
|
| Phenotype | 6 | 2014 | 6295 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 5 | 2 | 2001 | 259 | 0.120 |
Why?
|
| Genotype | 3 | 2013 | 4109 | 0.120 |
Why?
|
| Genes, APC | 1 | 1993 | 70 | 0.110 |
Why?
|
| Genes, Tumor Suppressor | 5 | 2012 | 1064 | 0.110 |
Why?
|
| RNA, Ribosomal | 1 | 2013 | 83 | 0.110 |
Why?
|
| Proportional Hazards Models | 5 | 2014 | 4988 | 0.110 |
Why?
|
| Surgical Instruments | 1 | 2013 | 138 | 0.110 |
Why?
|
| Cell Growth Processes | 1 | 2013 | 342 | 0.110 |
Why?
|
| Laparotomy | 2 | 2011 | 211 | 0.110 |
Why?
|
| Accidents, Aviation | 1 | 1992 | 7 | 0.110 |
Why?
|
| Breast Neoplasms, Male | 2 | 2013 | 229 | 0.110 |
Why?
|
| CCAAT-Enhancer-Binding Protein-delta | 1 | 2012 | 13 | 0.110 |
Why?
|
| Aircraft | 1 | 1992 | 28 | 0.110 |
Why?
|
| Spironolactone | 1 | 2012 | 22 | 0.110 |
Why?
|
| Cell Cycle Proteins | 2 | 2012 | 2045 | 0.110 |
Why?
|
| Ireland | 1 | 2012 | 30 | 0.110 |
Why?
|
| Respiration Disorders | 1 | 1992 | 45 | 0.110 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 1993 | 108 | 0.110 |
Why?
|
| Postmenopause | 2 | 2012 | 378 | 0.110 |
Why?
|
| Radiotherapy | 2 | 2018 | 1824 | 0.110 |
Why?
|
| Microtubules | 2 | 2012 | 270 | 0.110 |
Why?
|
| Sterilization | 1 | 2002 | 13 | 0.110 |
Why?
|
| Intraoperative Care | 1 | 2013 | 259 | 0.110 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2014 | 503 | 0.110 |
Why?
|
| Nuclear Envelope | 1 | 2012 | 39 | 0.110 |
Why?
|
| Adenylate Kinase | 1 | 2012 | 36 | 0.110 |
Why?
|
| Estrogen Receptor beta | 1 | 2012 | 155 | 0.100 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 3 | 1 | 2011 | 10 | 0.100 |
Why?
|
| General Practice | 1 | 2011 | 9 | 0.100 |
Why?
|
| Factor Analysis, Statistical | 1 | 2012 | 356 | 0.100 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2012 | 208 | 0.100 |
Why?
|
| Genes, BRCA2 | 2 | 2008 | 309 | 0.100 |
Why?
|
| Diuretics | 1 | 2012 | 170 | 0.100 |
Why?
|
| Estrogen Antagonists | 1 | 2012 | 184 | 0.100 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2010 | 566 | 0.100 |
Why?
|
| Standard of Care | 1 | 2012 | 243 | 0.100 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 2011 | 73 | 0.100 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2012 | 170 | 0.100 |
Why?
|
| Needs Assessment | 1 | 2012 | 233 | 0.100 |
Why?
|
| Fistula | 1 | 1991 | 76 | 0.100 |
Why?
|
| Genes, BRCA1 | 2 | 2008 | 387 | 0.100 |
Why?
|
| Fibroadenoma | 1 | 2010 | 25 | 0.100 |
Why?
|
| Adolescent | 5 | 2013 | 31252 | 0.100 |
Why?
|
| Nipples | 1 | 1991 | 132 | 0.100 |
Why?
|
| Western Australia | 2 | 2012 | 7 | 0.100 |
Why?
|
| Pancreatectomy | 2 | 2013 | 652 | 0.100 |
Why?
|
| Gastrectomy | 3 | 2005 | 451 | 0.100 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2013 | 362 | 0.100 |
Why?
|
| Health Priorities | 1 | 2010 | 40 | 0.100 |
Why?
|
| Intracellular Space | 1 | 2010 | 77 | 0.100 |
Why?
|
| Logistic Models | 3 | 2012 | 3441 | 0.100 |
Why?
|
| Stress, Physiological | 1 | 2014 | 492 | 0.090 |
Why?
|
| Specimen Handling | 1 | 2012 | 299 | 0.090 |
Why?
|
| Aspirin | 1 | 2014 | 455 | 0.090 |
Why?
|
| Triazoles | 2 | 2012 | 617 | 0.090 |
Why?
|
| Keratinocytes | 2 | 2011 | 241 | 0.090 |
Why?
|
| Antimitotic Agents | 1 | 2010 | 8 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 521 | 0.090 |
Why?
|
| Mutant Proteins | 1 | 2011 | 234 | 0.090 |
Why?
|
| Nitriles | 2 | 2012 | 906 | 0.090 |
Why?
|
| Mammography | 4 | 2013 | 1010 | 0.090 |
Why?
|
| Acute Disease | 2 | 2007 | 2422 | 0.090 |
Why?
|
| Epirubicin | 1 | 2010 | 157 | 0.090 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2012 | 324 | 0.090 |
Why?
|
| Oncogenes | 4 | 2007 | 673 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 1 | 2011 | 543 | 0.090 |
Why?
|
| Trastuzumab | 1 | 2012 | 696 | 0.090 |
Why?
|
| Population Surveillance | 1 | 2013 | 627 | 0.090 |
Why?
|
| Safety Management | 1 | 2011 | 132 | 0.090 |
Why?
|
| Genome | 1 | 2013 | 672 | 0.090 |
Why?
|
| Melanoma | 3 | 2013 | 5317 | 0.090 |
Why?
|
| Transcription, Genetic | 4 | 2012 | 3154 | 0.090 |
Why?
|
| Loss of Heterozygosity | 3 | 2001 | 602 | 0.090 |
Why?
|
| Phosphoserine | 2 | 1999 | 107 | 0.090 |
Why?
|
| Risk Factors | 7 | 2013 | 17523 | 0.090 |
Why?
|
| Spleen | 1 | 2012 | 676 | 0.090 |
Why?
|
| Tissue Expansion | 1 | 1990 | 71 | 0.090 |
Why?
|
| Conserved Sequence | 1 | 2011 | 469 | 0.090 |
Why?
|
| Caspase 3 | 1 | 2010 | 471 | 0.090 |
Why?
|
| Organoplatinum Compounds | 1 | 2012 | 702 | 0.090 |
Why?
|
| Research Design | 2 | 2012 | 1544 | 0.090 |
Why?
|
| Transcription Factors | 2 | 2012 | 5270 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 6 | 2011 | 5395 | 0.090 |
Why?
|
| Glycoproteins | 1 | 2013 | 747 | 0.090 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2010 | 726 | 0.090 |
Why?
|
| Age Factors | 4 | 2013 | 5377 | 0.090 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2010 | 182 | 0.090 |
Why?
|
| Friends | 1 | 2009 | 24 | 0.090 |
Why?
|
| Collagen | 1 | 2012 | 752 | 0.080 |
Why?
|
| Chromosome Disorders | 2 | 2001 | 417 | 0.080 |
Why?
|
| Artificial Intelligence | 1 | 2013 | 388 | 0.080 |
Why?
|
| Linear Models | 1 | 2012 | 1085 | 0.080 |
Why?
|
| Tubulin Modulators | 1 | 2008 | 65 | 0.080 |
Why?
|
| Recurrence | 3 | 2012 | 4758 | 0.080 |
Why?
|
| Mutation, Missense | 1 | 2014 | 1152 | 0.080 |
Why?
|
| Chromatography, Liquid | 1 | 2010 | 342 | 0.080 |
Why?
|
| Disease Progression | 3 | 2012 | 6682 | 0.080 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 980 | 0.080 |
Why?
|
| Laparoscopy | 1 | 1997 | 1225 | 0.080 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2012 | 622 | 0.080 |
Why?
|
| Social Class | 1 | 2010 | 310 | 0.080 |
Why?
|
| Evaluation Studies as Topic | 4 | 2013 | 418 | 0.080 |
Why?
|
| Nuclear Proteins | 5 | 2011 | 3343 | 0.080 |
Why?
|
| Comorbidity | 2 | 2013 | 2352 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 1165 | 0.080 |
Why?
|
| Blotting, Northern | 2 | 2004 | 682 | 0.080 |
Why?
|
| Drug Discovery | 1 | 2010 | 324 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2009 | 287 | 0.080 |
Why?
|
| Organ Size | 1 | 2009 | 690 | 0.080 |
Why?
|
| Oncogene Proteins | 1 | 1990 | 354 | 0.080 |
Why?
|
| Carcinoma, Lobular | 2 | 2010 | 611 | 0.080 |
Why?
|
| Alternative Splicing | 1 | 2011 | 584 | 0.080 |
Why?
|
| ErbB Receptors | 2 | 2012 | 2295 | 0.080 |
Why?
|
| Protein Array Analysis | 1 | 2010 | 501 | 0.080 |
Why?
|
| Embolism, Air | 1 | 1987 | 33 | 0.080 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2010 | 368 | 0.080 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2008 | 145 | 0.080 |
Why?
|
| Chi-Square Distribution | 2 | 2011 | 1323 | 0.080 |
Why?
|
| Thermography | 1 | 2007 | 59 | 0.070 |
Why?
|
| Reoperation | 1 | 2012 | 1382 | 0.070 |
Why?
|
| Genomic Instability | 1 | 2010 | 519 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2013 | 3639 | 0.070 |
Why?
|
| Quality of Life | 4 | 2013 | 4532 | 0.070 |
Why?
|
| Disease Management | 1 | 2012 | 1052 | 0.070 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2011 | 502 | 0.070 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2012 | 973 | 0.070 |
Why?
|
| Receptors, Cell Surface | 1 | 2010 | 862 | 0.070 |
Why?
|
| Evolution, Molecular | 1 | 2011 | 834 | 0.070 |
Why?
|
| Cyclin D | 1 | 2006 | 37 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2011 | 6207 | 0.070 |
Why?
|
| Cell Proliferation | 3 | 2014 | 7226 | 0.070 |
Why?
|
| Cisplatin | 2 | 2012 | 2432 | 0.070 |
Why?
|
| Evidence-Based Medicine | 2 | 2012 | 1085 | 0.070 |
Why?
|
| Age of Onset | 1 | 2008 | 827 | 0.070 |
Why?
|
| Preoperative Care | 1 | 2012 | 1529 | 0.070 |
Why?
|
| Trefoil Factor-1 | 2 | 1998 | 15 | 0.070 |
Why?
|
| Heart Diseases | 1 | 1992 | 732 | 0.070 |
Why?
|
| DNA Replication | 1 | 2010 | 744 | 0.070 |
Why?
|
| Tumor Burden | 1 | 2012 | 1987 | 0.070 |
Why?
|
| Blotting, Western | 4 | 2007 | 3536 | 0.070 |
Why?
|
| Vincristine | 1 | 2010 | 1511 | 0.070 |
Why?
|
| Fluorouracil | 1 | 2010 | 1944 | 0.070 |
Why?
|
| Neoplastic Stem Cells | 1 | 2014 | 1443 | 0.070 |
Why?
|
| Social Support | 2 | 2009 | 560 | 0.070 |
Why?
|
| Lymphoma, B-Cell | 1 | 2012 | 895 | 0.070 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2014 | 1215 | 0.070 |
Why?
|
| Professional Practice | 1 | 2005 | 82 | 0.070 |
Why?
|
| Antigens, CD | 1 | 2010 | 1385 | 0.070 |
Why?
|
| Drug Synergism | 1 | 2009 | 1313 | 0.070 |
Why?
|
| Postoperative Care | 1 | 2009 | 739 | 0.070 |
Why?
|
| Skin Neoplasms | 2 | 2013 | 4654 | 0.070 |
Why?
|
| Australia | 1 | 2005 | 225 | 0.070 |
Why?
|
| Young Adult | 3 | 2013 | 21445 | 0.060 |
Why?
|
| Insulin | 1 | 2011 | 1454 | 0.060 |
Why?
|
| Colonic Neoplasms | 1 | 1993 | 1390 | 0.060 |
Why?
|
| Myelopoiesis | 1 | 2005 | 31 | 0.060 |
Why?
|
| Family | 1 | 2009 | 736 | 0.060 |
Why?
|
| Retinoic Acid Receptor alpha | 1 | 2004 | 95 | 0.060 |
Why?
|
| Trust | 1 | 2005 | 99 | 0.060 |
Why?
|
| Mammary Glands, Human | 1 | 2006 | 184 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2011 | 5437 | 0.060 |
Why?
|
| Receptors, sigma | 1 | 2004 | 6 | 0.060 |
Why?
|
| Neoplasm Staging | 4 | 2013 | 13658 | 0.060 |
Why?
|
| Emergency Treatment | 1 | 2005 | 105 | 0.060 |
Why?
|
| Hemorheology | 1 | 2004 | 45 | 0.060 |
Why?
|
| Age Distribution | 2 | 2011 | 698 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2010 | 2054 | 0.060 |
Why?
|
| Accreditation | 1 | 2005 | 126 | 0.060 |
Why?
|
| Catheterization, Central Venous | 1 | 1987 | 354 | 0.060 |
Why?
|
| Genistein | 1 | 2004 | 73 | 0.060 |
Why?
|
| Isoflavones | 1 | 2004 | 72 | 0.060 |
Why?
|
| Pulsatile Flow | 1 | 2004 | 131 | 0.060 |
Why?
|
| Phosphoproteins | 1 | 1990 | 1152 | 0.060 |
Why?
|
| Chromosome Mapping | 5 | 2001 | 1471 | 0.060 |
Why?
|
| Hospitals, Teaching | 1 | 2004 | 120 | 0.060 |
Why?
|
| Decision Making | 1 | 2012 | 1287 | 0.060 |
Why?
|
| Health Services | 1 | 2004 | 105 | 0.060 |
Why?
|
| Papillomaviridae | 1 | 2007 | 624 | 0.060 |
Why?
|
| Registries | 3 | 2013 | 2170 | 0.060 |
Why?
|
| Clinical Competence | 2 | 2005 | 1270 | 0.060 |
Why?
|
| DNA Probes | 3 | 1993 | 217 | 0.060 |
Why?
|
| Retinoblastoma Protein | 1 | 2005 | 335 | 0.060 |
Why?
|
| Models, Cardiovascular | 1 | 2004 | 202 | 0.060 |
Why?
|
| Survival Rate | 3 | 2012 | 12221 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2012 | 1054 | 0.060 |
Why?
|
| Epithelial Cells | 1 | 2010 | 1818 | 0.060 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2004 | 365 | 0.060 |
Why?
|
| Constriction, Pathologic | 1 | 2004 | 310 | 0.060 |
Why?
|
| Hospitalization | 1 | 2012 | 2083 | 0.060 |
Why?
|
| Base Sequence | 5 | 2011 | 4917 | 0.060 |
Why?
|
| Down-Regulation | 4 | 2012 | 2074 | 0.060 |
Why?
|
| Intestinal Perforation | 1 | 2003 | 102 | 0.060 |
Why?
|
| Paclitaxel | 1 | 2010 | 1996 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2013 | 6100 | 0.060 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2003 | 119 | 0.060 |
Why?
|
| Molecular Biology | 1 | 2004 | 176 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2011 | 2022 | 0.050 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2006 | 690 | 0.050 |
Why?
|
| Gloves, Surgical | 1 | 1992 | 10 | 0.050 |
Why?
|
| Cardia | 2 | 1999 | 39 | 0.050 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2004 | 203 | 0.050 |
Why?
|
| Materials Testing | 1 | 1992 | 116 | 0.050 |
Why?
|
| DNA Repair | 1 | 2010 | 1872 | 0.050 |
Why?
|
| Liver | 1 | 2012 | 2961 | 0.050 |
Why?
|
| Cell Shape | 2 | 2012 | 128 | 0.050 |
Why?
|
| Tretinoin | 1 | 2004 | 623 | 0.050 |
Why?
|
| Drainage | 1 | 2004 | 416 | 0.050 |
Why?
|
| Feeding Behavior | 1 | 2008 | 808 | 0.050 |
Why?
|
| Molecular Sequence Data | 5 | 2011 | 6089 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 4320 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 5 | 2012 | 3203 | 0.050 |
Why?
|
| Algorithms | 1 | 2013 | 3890 | 0.050 |
Why?
|
| Anxiety | 1 | 2009 | 1179 | 0.050 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2003 | 334 | 0.050 |
Why?
|
| MCF-7 Cells | 2 | 2014 | 550 | 0.050 |
Why?
|
| Allelic Imbalance | 1 | 2001 | 41 | 0.050 |
Why?
|
| GPI-Linked Proteins | 2 | 2012 | 223 | 0.050 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2002 | 129 | 0.050 |
Why?
|
| Methylation | 2 | 2013 | 597 | 0.050 |
Why?
|
| Pancreatitis | 1 | 2003 | 267 | 0.050 |
Why?
|
| RNA, Small Interfering | 3 | 2012 | 2216 | 0.050 |
Why?
|
| Organ Specificity | 2 | 2012 | 699 | 0.050 |
Why?
|
| Cells, Cultured | 4 | 2012 | 5637 | 0.050 |
Why?
|
| Mice, Inbred CBA | 2 | 1991 | 78 | 0.050 |
Why?
|
| MicroRNAs | 2 | 2012 | 2947 | 0.050 |
Why?
|
| Karyotyping | 1 | 2002 | 1022 | 0.050 |
Why?
|
| Stomach | 1 | 2003 | 387 | 0.050 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2008 | 1248 | 0.050 |
Why?
|
| Mediastinum | 1 | 2002 | 268 | 0.050 |
Why?
|
| Monitoring, Physiologic | 1 | 2003 | 502 | 0.050 |
Why?
|
| Exercise | 1 | 2008 | 1183 | 0.050 |
Why?
|
| Proteasome Inhibitors | 2 | 2012 | 231 | 0.050 |
Why?
|
| Heterozygote | 3 | 1993 | 1020 | 0.050 |
Why?
|
| Phosphothreonine | 1 | 1999 | 20 | 0.040 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2001 | 270 | 0.040 |
Why?
|
| Structure-Activity Relationship | 2 | 2014 | 931 | 0.040 |
Why?
|
| Lung Neoplasms | 5 | 2010 | 11538 | 0.040 |
Why?
|
| Critical Care | 1 | 2005 | 770 | 0.040 |
Why?
|
| Protein Binding | 3 | 2013 | 3438 | 0.040 |
Why?
|
| Calcinosis | 2 | 2012 | 423 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2000 | 495 | 0.040 |
Why?
|
| Blotting, Southern | 2 | 1998 | 406 | 0.040 |
Why?
|
| Microfilament Proteins | 1 | 2001 | 487 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 2 | 1999 | 803 | 0.040 |
Why?
|
| Macrophages | 1 | 2005 | 1304 | 0.040 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2012 | 589 | 0.040 |
Why?
|
| Caregivers | 1 | 2004 | 677 | 0.040 |
Why?
|
| Cell Division | 4 | 2004 | 2489 | 0.040 |
Why?
|
| Genetic Markers | 2 | 1998 | 974 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2003 | 795 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 3 | 2013 | 2403 | 0.040 |
Why?
|
| England | 1 | 2007 | 75 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 2 | 1998 | 1823 | 0.040 |
Why?
|
| Length of Stay | 1 | 2004 | 1900 | 0.040 |
Why?
|
| Hernia, Inguinal | 1 | 1997 | 49 | 0.040 |
Why?
|
| Biological Specimen Banks | 1 | 2007 | 76 | 0.040 |
Why?
|
| RNA Interference | 2 | 2012 | 1408 | 0.040 |
Why?
|
| Esophageal Perforation | 1 | 1996 | 25 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2001 | 1442 | 0.040 |
Why?
|
| DNA | 4 | 1993 | 2693 | 0.040 |
Why?
|
| Computer Simulation | 2 | 2012 | 1529 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 1 | 2013 | 5061 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2012 | 4638 | 0.030 |
Why?
|
| Iatrogenic Disease | 1 | 1996 | 183 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 1999 | 1070 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2001 | 1299 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2012 | 4849 | 0.030 |
Why?
|
| DNA Damage | 3 | 2010 | 1954 | 0.030 |
Why?
|
| Shoulder Joint | 1 | 1995 | 82 | 0.030 |
Why?
|
| Range of Motion, Articular | 1 | 1995 | 144 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 2508 | 0.030 |
Why?
|
| CD24 Antigen | 1 | 2014 | 85 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 2 | 2012 | 3101 | 0.030 |
Why?
|
| Peptide Chain Initiation, Translational | 1 | 2013 | 26 | 0.030 |
Why?
|
| Biomarkers | 3 | 2008 | 5047 | 0.030 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2014 | 123 | 0.030 |
Why?
|
| Aging | 2 | 2013 | 1582 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2009 | 4757 | 0.030 |
Why?
|
| Child | 2 | 2011 | 29154 | 0.030 |
Why?
|
| Protein Stability | 1 | 2014 | 370 | 0.030 |
Why?
|
| Zinc Finger E-box Binding Homeobox 2 | 1 | 2012 | 42 | 0.030 |
Why?
|
| Hyaluronan Receptors | 1 | 2014 | 249 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2012 | 32 | 0.030 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2013 | 134 | 0.030 |
Why?
|
| Neoplasms, Basal Cell | 1 | 2012 | 33 | 0.030 |
Why?
|
| Photochemical Processes | 1 | 2012 | 8 | 0.030 |
Why?
|
| Snail Family Transcription Factors | 1 | 2012 | 120 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2011 | 2803 | 0.030 |
Why?
|
| Polydioxanone | 1 | 1992 | 7 | 0.030 |
Why?
|
| British Columbia | 1 | 2012 | 24 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2013 | 226 | 0.030 |
Why?
|
| Transcription Factor HES-1 | 1 | 2012 | 49 | 0.030 |
Why?
|
| Rodentia | 1 | 2012 | 65 | 0.030 |
Why?
|
| Polypropylenes | 1 | 1992 | 25 | 0.030 |
Why?
|
| Nevus | 1 | 2013 | 107 | 0.030 |
Why?
|
| Exons | 2 | 1993 | 1328 | 0.030 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2012 | 159 | 0.030 |
Why?
|
| Sample Size | 1 | 2012 | 202 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2012 | 1648 | 0.030 |
Why?
|
| Mastitis | 1 | 1991 | 12 | 0.030 |
Why?
|
| Pharmacogenetics | 1 | 2013 | 260 | 0.030 |
Why?
|
| Fiber Optic Technology | 1 | 1992 | 142 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2012 | 289 | 0.030 |
Why?
|
| HL-60 Cells | 1 | 2012 | 302 | 0.030 |
Why?
|
| Conscious Sedation | 1 | 1992 | 104 | 0.030 |
Why?
|
| Cell Size | 1 | 2012 | 136 | 0.030 |
Why?
|
| Sutures | 1 | 1992 | 86 | 0.030 |
Why?
|
| Europe | 1 | 2013 | 649 | 0.030 |
Why?
|
| NIMA-Interacting Peptidylprolyl Isomerase | 1 | 2011 | 60 | 0.030 |
Why?
|
| Basement Membrane | 1 | 2012 | 138 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2009 | 5687 | 0.030 |
Why?
|
| Curriculum | 1 | 1997 | 860 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1992 | 261 | 0.020 |
Why?
|
| BRCA2 Protein | 1 | 2013 | 358 | 0.020 |
Why?
|
| Anesthesia, Local | 1 | 1991 | 66 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2012 | 323 | 0.020 |
Why?
|
| Aneugens | 1 | 2010 | 1 | 0.020 |
Why?
|
| Reference Values | 1 | 1993 | 1099 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2012 | 311 | 0.020 |
Why?
|
| Endoglin | 1 | 2010 | 43 | 0.020 |
Why?
|
| Genes, Suppressor | 1 | 1990 | 25 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2014 | 1258 | 0.020 |
Why?
|
| Gene Knock-In Techniques | 1 | 2011 | 171 | 0.020 |
Why?
|
| Cytoprotection | 1 | 2010 | 66 | 0.020 |
Why?
|
| International Agencies | 1 | 2010 | 107 | 0.020 |
Why?
|
| Prostatic Neoplasms | 2 | 2004 | 5767 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2012 | 430 | 0.020 |
Why?
|
| Aurora Kinases | 1 | 2010 | 189 | 0.020 |
Why?
|
| France | 1 | 2010 | 108 | 0.020 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2013 | 332 | 0.020 |
Why?
|
| Immunoblotting | 2 | 2005 | 886 | 0.020 |
Why?
|
| BRCA1 Protein | 1 | 2013 | 493 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 1997 | 918 | 0.020 |
Why?
|
| Necrosis | 1 | 2012 | 580 | 0.020 |
Why?
|
| Thoracotomy | 1 | 2011 | 220 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2012 | 4053 | 0.020 |
Why?
|
| Feedback, Physiological | 1 | 2010 | 193 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2011 | 756 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2010 | 348 | 0.020 |
Why?
|
| Ubiquitination | 1 | 2012 | 575 | 0.020 |
Why?
|
| Zebrafish | 1 | 2012 | 463 | 0.020 |
Why?
|
| Gene Knockout Techniques | 1 | 2010 | 276 | 0.020 |
Why?
|
| Hypoxia | 1 | 1992 | 443 | 0.020 |
Why?
|
| Chromosomes | 1 | 1990 | 244 | 0.020 |
Why?
|
| Diffusion of Innovation | 1 | 2011 | 160 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1990 | 362 | 0.020 |
Why?
|
| DNA Primers | 1 | 2011 | 1399 | 0.020 |
Why?
|
| Cadherins | 1 | 2012 | 660 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 1225 | 0.020 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2010 | 280 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 945 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2010 | 4233 | 0.020 |
Why?
|
| Aneuploidy | 1 | 2010 | 369 | 0.020 |
Why?
|
| Propensity Score | 1 | 2012 | 750 | 0.020 |
Why?
|
| Heart Rate | 1 | 1992 | 737 | 0.020 |
Why?
|
| Histone Acetyltransferases | 1 | 2011 | 411 | 0.020 |
Why?
|
| Dogs | 1 | 2011 | 1155 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2009 | 231 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2012 | 1008 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 2 | 2005 | 1487 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 1217 | 0.020 |
Why?
|
| Micronuclei, Chromosome-Defective | 1 | 2008 | 34 | 0.020 |
Why?
|
| Pain | 1 | 1997 | 1658 | 0.020 |
Why?
|
| Colonoscopy | 1 | 1992 | 518 | 0.020 |
Why?
|
| Sirtuin 2 | 1 | 2008 | 19 | 0.020 |
Why?
|
| Tubulin | 1 | 2008 | 169 | 0.020 |
Why?
|
| Mitotic Index | 1 | 2008 | 162 | 0.020 |
Why?
|
| Sirtuins | 1 | 2008 | 44 | 0.020 |
Why?
|
| Cyclin E | 1 | 2010 | 267 | 0.020 |
Why?
|
| Tenascin | 1 | 2008 | 56 | 0.020 |
Why?
|
| Cell Line | 2 | 2010 | 5114 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2012 | 785 | 0.020 |
Why?
|
| Sirtuin 1 | 1 | 2008 | 89 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 2307 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2011 | 667 | 0.020 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2007 | 94 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2013 | 1863 | 0.020 |
Why?
|
| Epitopes | 2 | 1999 | 685 | 0.020 |
Why?
|
| Wound Healing | 1 | 1992 | 815 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2012 | 984 | 0.020 |
Why?
|
| Electrocardiography | 1 | 1992 | 1145 | 0.020 |
Why?
|
| Blood Pressure | 1 | 1992 | 1467 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2006 | 246 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2006 | 231 | 0.020 |
Why?
|
| Mammals | 1 | 2008 | 361 | 0.020 |
Why?
|
| Mitosis | 1 | 2008 | 615 | 0.020 |
Why?
|
| Patient Selection | 1 | 2013 | 2055 | 0.020 |
Why?
|
| Autophagy | 1 | 2012 | 927 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 1992 | 2283 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2008 | 383 | 0.020 |
Why?
|
| Cell Survival | 1 | 2012 | 3045 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 1945 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2008 | 1391 | 0.020 |
Why?
|
| Dyspepsia | 1 | 2006 | 103 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2006 | 660 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2013 | 2086 | 0.020 |
Why?
|
| Emotions | 1 | 2009 | 562 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2012 | 1491 | 0.020 |
Why?
|
| Phospholipase C delta | 1 | 2004 | 3 | 0.020 |
Why?
|
| U937 Cells | 1 | 2005 | 171 | 0.020 |
Why?
|
| Ethylenediamines | 1 | 2004 | 21 | 0.020 |
Why?
|
| Splenectomy | 1 | 2005 | 158 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2012 | 1664 | 0.020 |
Why?
|
| Type C Phospholipases | 1 | 2004 | 53 | 0.020 |
Why?
|
| Prevalence | 1 | 1992 | 3260 | 0.020 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2008 | 621 | 0.020 |
Why?
|
| Carbazoles | 1 | 2004 | 87 | 0.010 |
Why?
|
| Haloperidol | 1 | 2004 | 64 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2010 | 2450 | 0.010 |
Why?
|
| Peptides | 1 | 2010 | 1479 | 0.010 |
Why?
|
| Cell Movement | 1 | 2011 | 2466 | 0.010 |
Why?
|
| Immunoprecipitation | 1 | 2005 | 591 | 0.010 |
Why?
|
| Blood Vessels | 1 | 2004 | 217 | 0.010 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2013 | 2370 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2005 | 875 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2004 | 460 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 2004 | 475 | 0.010 |
Why?
|
| Hypertension | 1 | 2012 | 1503 | 0.010 |
Why?
|
| Cattle | 1 | 2004 | 783 | 0.010 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2013 | 2104 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 4938 | 0.010 |
Why?
|
| Calcium Signaling | 1 | 2004 | 284 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2004 | 614 | 0.010 |
Why?
|
| Occupational Health | 1 | 1992 | 95 | 0.010 |
Why?
|
| Caspases | 1 | 2004 | 661 | 0.010 |
Why?
|
| Equipment Failure | 1 | 1992 | 191 | 0.010 |
Why?
|
| Medical Staff, Hospital | 1 | 1992 | 118 | 0.010 |
Why?
|
| Rats | 1 | 1990 | 6086 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 2006 | 509 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2006 | 2292 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2006 | 1301 | 0.010 |
Why?
|
| Oligonucleotide Probes | 2 | 1990 | 130 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2010 | 4314 | 0.010 |
Why?
|
| Molecular Targeted Therapy | 1 | 2011 | 2330 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2008 | 2054 | 0.010 |
Why?
|
| Dietary Supplements | 1 | 2004 | 558 | 0.010 |
Why?
|
| Isoelectric Point | 1 | 1999 | 29 | 0.010 |
Why?
|
| Spodoptera | 1 | 1999 | 63 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2008 | 1589 | 0.010 |
Why?
|
| Brain | 1 | 1993 | 4113 | 0.010 |
Why?
|
| Lung | 1 | 2010 | 3151 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2004 | 925 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2005 | 1129 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 1999 | 334 | 0.010 |
Why?
|
| Hepatectomy | 1 | 2005 | 1011 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2006 | 3842 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1998 | 329 | 0.010 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 1999 | 243 | 0.010 |
Why?
|
| Heart Failure | 1 | 2012 | 2516 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1998 | 568 | 0.010 |
Why?
|
| Pedigree | 2 | 1992 | 1890 | 0.010 |
Why?
|
| Data Collection | 1 | 1999 | 620 | 0.010 |
Why?
|
| Paraffin Embedding | 1 | 1994 | 226 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2005 | 4078 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1999 | 2927 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 1999 | 1271 | 0.010 |
Why?
|
| Contusions | 1 | 1991 | 18 | 0.010 |
Why?
|
| Causality | 1 | 1992 | 178 | 0.010 |
Why?
|
| Wound Infection | 1 | 1991 | 54 | 0.010 |
Why?
|
| Genetic Therapy | 1 | 1998 | 1616 | 0.010 |
Why?
|
| Autoradiography | 1 | 1990 | 132 | 0.010 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 1990 | 68 | 0.010 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 1990 | 57 | 0.010 |
Why?
|
| Codon | 1 | 1990 | 241 | 0.010 |
Why?
|
| Hematoma | 1 | 1991 | 160 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 1991 | 512 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 1994 | 1450 | 0.010 |
Why?
|
| Adenoma | 1 | 1990 | 716 | 0.000 |
Why?
|
| Intestinal Mucosa | 1 | 1990 | 1081 | 0.000 |
Why?
|